Posted by Michael Wonder on 30 Aug 2022
Evusheld long-acting antibody combination approved for prevention and treatment of COVID-19 in Japan
30 August 2022 - First global approval for Evusheld as a COVID-19 treatment.
AstraZeneca's Evusheld (tixagevimab and cilgavimab, formerly AZD7442), a long-acting antibody combination, has been approved in Japan for both prevention (pre-exposure prophylaxis) and treatment of symptomatic disease caused by SARS-CoV-2 infection.
